

## Special Issue

# Innovative Treatments for Hospital-Acquired Multidrug-Resistant Bacterial Infections

### Message from the Guest Editors

The escalating prevalence of hospital-acquired multidrug-resistant bacterial infections (MDRIs) represents a dual crisis in modern medicine, demanding urgent innovation in antimicrobial therapies. Clinically, these infections lead to severe complications, prolonged hospitalizations, and increased mortality. Traditional antibiotics often fail against resistant strains, leaving limited treatment options and forcing reliance on last-resort drugs with significant toxicity. Economically, MDRIs impose staggering costs due to extended ICU stays, complex infection control measures, and the need for expensive salvage therapies burdening healthcare systems already under strain. Without novel interventions, such as phage therapy, next-generation antibiotics, and precision antimicrobial strategies, the financial and human toll will intensify. Investing into advanced therapeutics is not just a scientific priority but a public health necessity. We invite readers of this prestigious journal to contribute their recent discoveries regarding the fight against multidrug-resistant microorganisms.

### Guest Editors

Prof. Dr. Lucas de Paula Ramos

Prof. Dr. Cristina Pacheco-Soares

Dr. Hugo Vigerelli

Prof. Dr. Florence Carrouel

### Deadline for manuscript submissions

31 December 2025



## Antibiotics

an Open Access Journal  
by MDPI

Impact Factor 4.6  
CiteScore 8.7  
Indexed in PubMed



[mdpi.com/si/244945](https://mdpi.com/si/244945)

*Antibiotics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[antibiotics@mdpi.com](mailto:antibiotics@mdpi.com)

[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)





# Antibiotics

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.7  
Indexed in PubMed



[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)



## About the Journal

### Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

---

### Editor-in-Chief

Prof. Dr. Nicholas Dixon  
School of Chemistry and Molecular Bioscience, University of  
Wollongong, Wollongong, NSW 2522, Australia

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)